Drugs / Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03602612 | Sep 2018 → Jan 2023 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03602612 ↗ |
| Action | Deplete | “anti-BCMA-CAR-expressing T cells will specifically eliminate BCMA- expressing MM cells in patients” NCT03602612 ↗ |
| Modality | Cell therapy | “T-cells obtained by leukapheresis will be genetically modified to express an anti-BCMA CAR” NCT03602612 ↗ |